FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026287483> ?p ?o ?g. }

• W3026287483 endingPage "593" @default.
• W3026287483 startingPage "589" @default.
• W3026287483 abstract "Objective: To investigate the strong expression (S+) of P53 and BCL2 proteins in MYC/BCL2 double-expression DLBCL (DEL) and whether they can be used for the prognostic evaluation and stratified diagnosis of DELs. Methods: Tissue microarray were made by filed FFPE blocks of 174 DLBCL cases. The translocation of MYC, BCL2 and BCL6 genes were detected by FISH, and the proteins were detected by IHC. Data of clinicopathologic features and follow up of patients were collected and OS (overall survival) and PFS (progression free survival) were analyzed by statistics. Results: Eight double-hit lymphomas (DHLs) were identified in all cases, and 45 DELs were selected from 166 remaining cases, which have no significant difference in OS and PFS compared with non-DEL cases (P=0.668 and P=0.790) . Of 42 DEL-cases with follow up data, 24 cases with P53+ or/and BCL2 (S+) are significantly shorter OS and PFS than others (P=0.003 and P=0.000) , in which the cases with P53+/BCL2 (S+) co-expression were the worst prognosis, and P53/BCL2 co-weaker positive DEL cases even have superior OS and PFS than those non-DELs. Although statistics showed that the cases of P53+ or/and BCL2 (S+) have a lower OS and PFS in total cases (P=0.063 and P=0.024) , it is not the case when the DEL-cases take out from total cases, that is the cases with P53+ or/and BCL2 (S+) are as similar OS and PFS as others in non-DEL group (P=0.590 and P=0.550) . Conclusion: The strong expression of P53 and BCL2 proteins can be used as indicators of stratified diagnosis and poor prognosis of DEL.目的： 探讨P53及BCL2蛋白强表达在MYC和BCL2双表达淋巴瘤（DEL）分层诊断及预后预测中的作用。 方法： 以2011年1月至2016年12月174例DLBCL患者的存档蜡块制作组织芯片，应用免疫组化和FISH技术对相应标记物进行检测并筛选出DEL病例，结合临床病理特征及随访资料进行统计学分析。 结果： 筛选出DEL病例45例（27.1%），生存分析显示DEL与非DEL病例的总生存（OS）和无进展生存（PFS）无显著性差异（P=0.668和P=0.790）。在随访到的42例DEL病例中，P53和BCL2蛋白单独（P=0.012和P=0.032，P=0.027和P=0.004）或两者联合强表达（P=0.003和P=0.000）的OS和PFS均显著缩短，其中P53和BCL2蛋白联合强表达预后最差，而P53和BCL2蛋白同时弱表达和/或阴性的DEL病例预后甚至优于非DEL病例。虽然总病例中P53阳性和/或BCL2强阳性患者的OS和PFS也明显缩短（P=0.063和P=0.024），但在去除DEL病例的影响后，单独非DEL病例中P53阳性或/和BCL2强阳性对OS和PFS则无显著影响（P=0.590和P=0.550）。 结论： P53和BCL2蛋白强表达可作为双表达淋巴瘤进一步分层诊断和评估预后的生物学指标。." @default.
• W3026287483 created "2020-05-29" @default.
• W3026287483 creator A5001659843 @default.
• W3026287483 creator A5006621752 @default.
• W3026287483 creator A5018866860 @default.
• W3026287483 creator A5035200543 @default.
• W3026287483 creator A5048566863 @default.
• W3026287483 creator A5066273890 @default.
• W3026287483 creator A5067592367 @default.
• W3026287483 creator A5069890679 @default.
• W3026287483 creator A5078752570 @default.
• W3026287483 creator A5078802906 @default.
• W3026287483 creator A5082854153 @default.
• W3026287483 creator A5086755660 @default.
• W3026287483 date "2019-07-14" @default.
• W3026287483 modified "2023-09-27" @default.
• W3026287483 title "[Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL]." @default.
• W3026287483 cites W1203878641 @default.
• W3026287483 cites W2007050465 @default.
• W3026287483 cites W2097561270 @default.
• W3026287483 cites W2129272684 @default.
• W3026287483 cites W2138484914 @default.
• W3026287483 cites W2158267770 @default.
• W3026287483 cites W2159862107 @default.
• W3026287483 cites W2310716991 @default.
• W3026287483 cites W2530587853 @default.
• W3026287483 cites W2559431510 @default.
• W3026287483 cites W2588651118 @default.
• W3026287483 cites W2616581951 @default.
• W3026287483 cites W2625300447 @default.
• W3026287483 cites W2762450632 @default.
• W3026287483 cites W2788380546 @default.
• W3026287483 cites W2797584152 @default.
• W3026287483 cites W2811018964 @default.
• W3026287483 cites W2903454518 @default.
• W3026287483 doi "https://doi.org/10.3760/cma.j.issn.0253-2727.2019.07.010" @default.
• W3026287483 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7364905" @default.
• W3026287483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32397023" @default.
• W3026287483 hasPublicationYear "2019" @default.
• W3026287483 type Work @default.
• W3026287483 sameAs 3026287483 @default.
• W3026287483 citedByCount "3" @default.
• W3026287483 countsByYear W30262874832021 @default.
• W3026287483 countsByYear W30262874832022 @default.
• W3026287483 crossrefType "journal-article" @default.
• W3026287483 hasAuthorship W3026287483A5001659843 @default.
• W3026287483 hasAuthorship W3026287483A5006621752 @default.
• W3026287483 hasAuthorship W3026287483A5018866860 @default.
• W3026287483 hasAuthorship W3026287483A5035200543 @default.
• W3026287483 hasAuthorship W3026287483A5048566863 @default.
• W3026287483 hasAuthorship W3026287483A5066273890 @default.
• W3026287483 hasAuthorship W3026287483A5067592367 @default.
• W3026287483 hasAuthorship W3026287483A5069890679 @default.
• W3026287483 hasAuthorship W3026287483A5078752570 @default.
• W3026287483 hasAuthorship W3026287483A5078802906 @default.
• W3026287483 hasAuthorship W3026287483A5082854153 @default.
• W3026287483 hasAuthorship W3026287483A5086755660 @default.
• W3026287483 hasConcept C104317684 @default.
• W3026287483 hasConcept C126322002 @default.
• W3026287483 hasConcept C138626823 @default.
• W3026287483 hasConcept C143998085 @default.
• W3026287483 hasConcept C159654299 @default.
• W3026287483 hasConcept C193270364 @default.
• W3026287483 hasConcept C203014093 @default.
• W3026287483 hasConcept C204232928 @default.
• W3026287483 hasConcept C2777537477 @default.
• W3026287483 hasConcept C2778453870 @default.
• W3026287483 hasConcept C2779338263 @default.
• W3026287483 hasConcept C2780739268 @default.
• W3026287483 hasConcept C3019894029 @default.
• W3026287483 hasConcept C502942594 @default.
• W3026287483 hasConcept C54355233 @default.
• W3026287483 hasConcept C71924100 @default.
• W3026287483 hasConcept C86803240 @default.
• W3026287483 hasConcept C96926380 @default.
• W3026287483 hasConceptScore W3026287483C104317684 @default.
• W3026287483 hasConceptScore W3026287483C126322002 @default.
• W3026287483 hasConceptScore W3026287483C138626823 @default.
• W3026287483 hasConceptScore W3026287483C143998085 @default.
• W3026287483 hasConceptScore W3026287483C159654299 @default.
• W3026287483 hasConceptScore W3026287483C193270364 @default.
• W3026287483 hasConceptScore W3026287483C203014093 @default.
• W3026287483 hasConceptScore W3026287483C204232928 @default.
• W3026287483 hasConceptScore W3026287483C2777537477 @default.
• W3026287483 hasConceptScore W3026287483C2778453870 @default.
• W3026287483 hasConceptScore W3026287483C2779338263 @default.
• W3026287483 hasConceptScore W3026287483C2780739268 @default.
• W3026287483 hasConceptScore W3026287483C3019894029 @default.
• W3026287483 hasConceptScore W3026287483C502942594 @default.
• W3026287483 hasConceptScore W3026287483C54355233 @default.
• W3026287483 hasConceptScore W3026287483C71924100 @default.
• W3026287483 hasConceptScore W3026287483C86803240 @default.
• W3026287483 hasConceptScore W3026287483C96926380 @default.
• W3026287483 hasIssue "7" @default.
• W3026287483 hasLocation W30262874831 @default.
• W3026287483 hasOpenAccess W3026287483 @default.
• W3026287483 hasPrimaryLocation W30262874831 @default.
• W3026287483 hasRelatedWork W1982245520 @default.

• next